A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects with Chronic Spinal Cord Injury – A Randomized, Double-Blind, Placebo-Controlled MulticEnter Phase 3 Trial (RESTORE)

Study overview

The RESTORE study is a randomized, double-blind, placebo-controlled trial for individuals 18-75 years old with chronic tetraplegia due to traumatic, cervical spinal cord injury (SCI). Participants will perform daily subcutaneous injections of NVG-291 for 12 weeks, followed by 4 weeks of observation. Learn more about the study with NervGen Pharma Corp.

Study eligibility

To take part in this study, participants must:

• Be aged 18–75
• Have chronic tetraplegia due to traumatic SCI (≥C7; ASIA Impairment Scale C or D)
• Are 1-10 years post injury